Patients with rare skin cancer face 40% recurrence rate
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40% — markedly higher than the recurrence rates for cand other skin cancers, according to… read more.
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40% — markedly higher than the recurrence rates for cand other skin cancers, according to… read more.
Researchers from a phase 3 clinical trial report that addition of the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy significantly prolongs the survival of men with metastatic,… read more.
Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men… read more.
University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.
Trametinib, a drug treatment for skin and lung cancers, appears to slow the progression of low-grade serous cancer of the ovary and to increase the number of patients… read more.
Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.
Seagen Inc. announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional… read more.
In cancer research, it has long been known that lactic acid, or lactate, is produced in large quantities by cancer cells and that this lactic acid disrupts our… read more.
Two recent reports show how hard lung cancer outcomes have been impacted as a result of the covid-19 pandemic, according to Professor Robert Rintoul, chair of the UK… read more.
BeiGene, Ltd. announced that Brukinsa (zanubrutinib) has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL)… read more.
Eisai Co., Ltd. and Merck Inc., announced that the European Commission has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai,… read more.
Merck Inc., announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.